key: cord-0759327-fg1sjnak
authors: Wang, Zhong; Gao, Xiang; Ma, He Miao Xiaochun; Ding, Renyu
title: Understanding COVID-19-associated coagulopathy: From PIC to SIC or DIC
date: 2021-03-27
journal: nan
DOI: 10.1016/j.jointm.2021.03.002
sha: be3959d9cf1f19f4025ce2fc7172a0b52ced5735
doc_id: 759327
cord_uid: fg1sjnak

Coagulopathy, characterized by a high D-dimer level, is a common pathological occurrence in coronavirus disease 2019 (COVID-19) and is associated with poor prognosis. Severe cases with COVID-19 is associated with a significantly higher risk of deep vein thrombosis and acute pulmonary embolism. Pulmonary intravascular coagulopathy is the characteristic coagulopathy in COVID-19. Unlike sepsis-induced coagulopathy and disseminated intravascular coagulation, which are manifestations of systemic coagulopathy, pulmonary intravascular coagulopathy is a manifestation of a local coagulation disorder in the lung. The progression from pulmonary intravascular coagulopathy to sepsis-induced coagulopathy or disseminated intravascular coagulation in the context of COVID-19 may indicate that the patient's coagulation dysfunction has progressed from local to systemic. Exploring the associated coagulation disease will aid in the understanding of the pathophysiological mechanisms underlying severe COVID-19.

Coronavirus disease 2019 (COVID-19) has become a global pandemic since it was first reported in Wuhan, China in December 2019. Despite its significant health and economic impacts, neither specific treatments nor effective antiviral drugs have been developed to date to combat this disease [1] .

COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The binding of the SARS-CoV-2 spike protein to angiotensin-converting enzyme 2 (ACE2) receptors, which are highly expressed in type II pneumocytes [2] , initiates marked inflammatory cell infiltration in lung tissue that results in a pulmonary and/or systemic inflammatory response [3] . The lung is the primary target organ of SARS-CoV-2, and acute lung injury and acute respiratory distress syndrome (ARDS) are the most common complications observed in COVID-19 patients [4] . However, SARS-CoV-2 infection has also been reported to be associated with coagulation disorders, characterized by high D-dimer levels, which are associated with poor prognosis [5] [6] [7] . Autopsy studies on COVID-19 patients have highlighted the presence of significant pulmonary microvascular disseminated microthrombosis [8, 9] . In addition, emerging data suggest that severe COVID-19 is associated with a significantly higher risk of deep vein thrombosis (DVT) and acute pulmonary embolism (APE) [10, 11] .

However, because the characteristics of coagulopathy of COVID-19 are different from those of sepsis-induced coagulopathy (SIC) and disseminated intravascular coagulation (DIC), a new term has been presented, namely, pulmonary intravascular coagulopathy (PIC) [12] .

The initial coagulopathy in COVID-19 is characterized by a significant increase in D-dimer levels [5] [6] [7] . Meanwhile, abnormalities in prothrombin time (PT), activated partial thromboplastin time (APTT), and platelet count are relatively uncommon or mild [ Table 1 ] [5-7, 10, 13-18]. In addition, a high fibrinogen level may indicate hypercoagulability, and thromboelastographic studies have revealed hypercoagulation in patients with 20] . Moreover, high incidences of DVT and APE have been reported in COVID-19 patients [10, 11] . Given the characteristics of COVID-19 associated coagulopathy, several guidelines recommend routine heparin anticoagulation treatment [21, 22] ; however, the timing and indication of anticoagulant treatment remain controversial [23] . Moreover, there are reports of persistently high incidence rates of DVT and APE in patients with severe COVID-19 admitted to the intensive care unit (ICU) despite the administration of a therapeutic dose of heparin [24] . Nevertheless, Tang et al [15] suggested that heparin anticoagulation may reduce mortality in patients whose D-dimer levels are increased by more than six-fold or those with SIC scores ≥4. suggesting that PIC is not associated with MAS. These observations highlight the need to further explore the mechanism underlying the inflammatory response and the association between inflammation and coagulation in COVID-19-associated acute lung injury.

There are no standardized diagnostic criteria for sepsis-associated coagulation disease, and the SIC (Table 2) .

PIC is the characteristic coagulation dysfunction in COVID-19 patients; however, it remains unclear whether the changes in coagulation progress linearly from PIC to SIC and then to DIC. A comparison between the incidence of coagulopathy in patients with COVID-19 and SARS is shown in Table 3 Table 4 [10, 11, 24, 36, [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] . These studies showed a markedly high incidence of thrombotic complications, particularly APE, in patients with COVID-19 (Table 4 ) [10, 38] . This highlights that COVID-19-induced coagulation disorders are concentrated in the lung;

however, systemic coagulation dysfunction may not be significant or specific.

The limited evidence available indicates that the coagulopathy associated with non-COVID-19 pneumonia or ARDS is different from the PIC caused by SARS-CoV-2. The incidence of pulmonary embolism in COVID-19 patients with ARDS is six-fold higher than that in non-ARDS COVID-19 patients [10] . A recent autopsy study revealed severe endothelial cell damage and extensive microvascular thrombosis in the lungs of COVID-19 patients and reported widespread thrombosis with microangiopathy [9]. The incidence of alveolar capillary microthrombus and the amount of new vessel growth (predominantly through a mechanism of intussusceptive angiogenesis) in patients with COVID-19 are substantially higher than those in influenza A (H1N1) patients [9]. Our limited clinical experience and a review of existing studies also indicate that the incidence of massive alveolar effusion (which is generally caused by an increase in pulmonary microvascular permeability) in influenza A patients with severe ARDS is significantly higher than that seen in COVID-19 patients. This highlights the need to further explore the differences in clinical manifestations and pathophysiological mechanisms between COVID-19 and influenza A patients. Because of the central role of endothelial cell injury in coagulopathy, we propose the following hypothesis [ Figure 1 ]: The pulmonary microvascular endothelial cell injuries in H1N1-infected patients might be mainly caused by pulmonary inflammatory responses, while the endothelial cell damage seen in COVID-19 patients might be mainly caused by the direct invasion of SARS-CoV-2. COVID-19-induced PIC may be associated with ACE2, a major component of the renin-angiotensin-aldosterone system, which is involved in the regulation of inflammatory coagulation processes and the fibrinolysis system [3, 12, 48].

SARS-CoV-2 is more pathogenic than SARS-CoV-1 because it has an at least 10-to 20-fold higher binding affinity for ACE2 [49] . This allows SARS-CoV-2 to more efficiently enter host cells, replicate, and damage cells, particularly endothelial cells [2, 3]. Importantly, ACE2 is considered to have anti-inflammatory properties [50] , which may explain the occult onset and protracted duration of COVID-19 [ Figure 1 ].

Overall, the main differences between PIC, SIC, and DIC are that PIC is the manifestation of a local coagulation disorder in the lung, while SIC and DIC are the manifestations of systemic coagulopathy.

The possible mechanisms underlying PIC are as follows: (1) Thrombus formation and fibrin deposition in the lung activate the fibrinolytic system, resulting in an increase in D-dimer concentrations; or (2) although pulmonary thrombosis consumes clotting factors, these can be supplemented by the liver; thus, the changes in PT and APTT may be masked. Because fibrinogen is an acute-phase protein, the liver increases fibrinogen synthesis when systemic inflammation occurs, thereby increasing the concentration of fibrinogen in COVID-19 patients. When COVID-19 patients progress to SIC or DIC, this may indicate that their coagulation dysfunction has progressed from local to systemic. Multiple factors may be involved in the progression of PIC to SIC/DIC, including viremia, liver dysfunction, secondary infection, secondary multiple organ dysfunction, shock, severe hypoxia, and/or iatrogenic factors (e.g., continuous renal replacement therapy and frequent blood drawing).

1. Is PIC unique to COVID-19 or is it a characteristic of viral pneumonia-associated coagulopathy in general? The incidence of APE in influenza A and SARS is also high, while the incidence of DIC in SARS is only 2.5% (Table 4 ) [38] . Currently, there are relatively few reports on the differences in coagulopathy between COVID-19 and other types of viral pneumonia [51] , and further research is needed.

2. Which is the COVID-19 associated embolism, APE or pulmonary artery thrombosis (PAT)?

Studies have shown that the incidence of DVT is significantly lower than that of APE in patients with COVID-19 (Table 4) . Consequently, some researchers believe that PAT may be the accurate term for COVID-19 associated embolism [52] [53] [54] , as thrombi might form de novo in the pulmonary vascular system, rather than originating at a distant site. In addition, the high incidence of alveolar capillary microthrombus in COVID-19 patients [9]might indicate a more significant localized activation of the coagulation system and risk of thrombosis in the lung, rather than a systemic involvement.

3. Is pulmonary thrombosis associated with right ventricular dysfunction or PH? Transthoracic echocardiography is a technique commonly used to evaluate right ventricular function in COVID-19 patients [55] . Dweck et al [56] observed a 33% incidence of right heart dysfunction, a 15% incidence of right ventricular dilatation, and an 8% incidence of PH. Right heart dysfunction and PH in COVID-19 patients are caused by a variety of factors, such as ARDS, increased pulmonary vascular resistance due to hypoxia, and pulmonary thrombosis [11] . Van Dongen and colleagues reported a case of a patient with COVID-19 who developed PH diagnosed by echocardiography, without pulmonary embolism, likely as a result of residual marked pulmonary parenchymal abnormalities in combination with microvascular damage of the pulmonary arteries [57] .

4. Is the absence of a D-dimer component for determining the SIC score reasonable? The clinical significance of the fibrinolysis system in sepsis-related coagulation diseases merits re-examination.

Studies have reported that the fibrinolytic shutdown that occurs in sepsis is characterized by increased plasminogen activator inhibitor 1 activity that leads to a low D-dimer level [58, 59] .

These results are in contrast to the coagulation changes observed in patients with COVID-19.

In conclusion, PIC is the characteristic coagulopathy in COVID-19 patients. Unlike SIC and DIC, which are manifestations of systemic coagulopathy, PIC is a manifestation of a local coagulation disorder in the lung. The progression from PIC to SIC or DIC in COVID-19 may indicate that a patient's coagulation dysfunction has progressed from local to systemic. In this context, exploring the associated coagulation disease will aid in the understanding of the pathophysiological mechanisms of severe COVID-19.

This work was supported by the Scientific Project of The Educational Department of Liaoning Province (Grant no. ZF2019010) and China Medical University's COVID-19 prevention-and control-related research projects. The sponsors did not play any role in the study design; collection, analysis, or interpretation of data; writing of the report; or deciding to submit the article for publication.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 

Haematological manifestati ons in patients with severe acute respiratory syndrome: retrospective analysis

Inciden ce of thrombotic complications in critically ill ICU patients with COVID-19

Incidence of asymptomatic deep vein thrombosis in patien ts with COVID-19 pneumonia and elevated D-dimer levels

A utopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

Empirical sys temic anticoagulation is associated with decreased venous thromboembolism in critically ill i nfluenza A H1N1 acute respiratory distress syndrome patients

Thromboembolic events in patients with severe pandemic influenza A/H1N1

Intensive-care patients with s evere novel influenza A (H1N1) virus infection -Michigan

Autop sy findings in eight patients with fatal H1N1 influenza

Lung pathol ogy in fatal novel human influenza A (H1N1) infection

Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: chall enges in determining a SARS diagnosis

Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome

The renin-angiotensin-aldosterone system and fibrinolysis

SAR S-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Prov en Protease Inhibitor

Angi otensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19)

Coagulation disorders in coronavirus infected patients: C OVID-19, SARS-CoV-1, MERS-CoV and lessons from the past

Pulmonary artery thro mbosis in a patient with severe acute respiratory syndrome

Pulmonary haemangiosarcoma with main pulmonary artery thrombosis imitating subacute pulmonary embolism with infarction

Massive pulmonary art ery thrombosis, pulmonary hypertension and untreated atrial septal defect

Acute Right Ventricular Dysfunction in a Critically Ill Patient with COVID-19. CASE (Phila)

Global evaluatio n of echocardiography in patients with COVID-19

Unusually Rapid Development of Pulmonary Hypertension and Right Ventric ular Failure after COVID-19 Pneumonia

Platelet Drop a nd Fibrinolytic Shutdown in Patients With Sepsis

Antifibrinolytic Therapy and Perio perative Considerations